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INTRODUCTION 
 
 “Diabetes is a dreadful distress and burden, where flesh and limbs 
melts into urine, patients don’t stop drinking water and the flow is  
continuous without interruption like opening of aqueduct.” Life is 
disagreeable and full of discomfort, thirst is impossible to satisfy, an 
insatiable appetite, passing litres of urine, not appropriate to the intake of 
fluids. If they refrain from drinking, their mouth seem dry and  body gets 
roasted  and their viscera seems to wither or parch with intense heat and 
excoriate as pointed in second century A. D  by Aretaeus of Cappadocia. 
              Diabetes mellitus is a disease of ancient times which is a 
complex  metabolic disorder characterised by chronic hyperglycemia 
contributed by the dysregulation of carbohydrate, fat and protein 
metabolism  due  to  decreased secretion of  insulin, defect in the 
utilization of  glucose, and increased production of  glucose.
[1]
 World 
Health Organisation classified diabetes mellitus according to the etiology 
into type 1, type 2 , gestational diabetes and other types.
[2] 
                Diabetes mellitus imposes an increased global burden 
contributing to both micro vascular complications like retinopathy, 
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nephropathy, and macro vascular complication like stroke and coronary 
artery disease.It is the leading cause of vision loss
[3]
, lower limb 
amputation
[4]
, renal failure. Globally it is the fifth major cause of death.
 
In 2010, 285 million people were suffering from this disease and 
hence no doubt it is the most common non communicable disease 
globally due to changing cultural habits and rapid westernisation. 
Prevalence of diabetes in India is 62.4 million and hence this study was 
done to analyse causal association of obesity with diabetic complication 
namely diabetic retinopathy. 
The pathogenesis of micro vascular complication is through 
chronic intracellular hyperglycemia   and the tissues  are  affected by 
various  mechanisms like more  influx of glucose  through the polyol   
pathway, increased  production of advanced glycated end products and 
raised formation of free radicals in mitochondria. One such important 
micro vascular complication of diabetes is retinopathy. 
Diabetic retinopathy causes frightening vision loss in working age. 
Though, cataract and refractive error were the leading cause of impaired 
vision in Asia, as the proportion of diabetes mellitus multiplies here in 
Asia, diabetic retinopathy has to be thoroughly screened for, as per the 
saying   “prevention is better than cure.”Diabetic patient have to be 
 
 12 
screened periodically to avoid the untoward consequence of vision loss 
due to diabetic retinopathy. 
World Health Organization has published a statistical report that 
diabetic population in Asia especially in India and China is 52.4 million.  
This number is forecasted to multiply to 121.8 million by 2030,
[5]
 due to 
the lack of knowledge and information regarding the modifiable risk 
factors. By 2030, the number of senior citizens is expected to climb by 
168 percentage in Asia 
[5]
 and due to the increasing prevalence of diabetes 
mellitus in the younger generation due to changing cultural habits, 
westernization  allows the time interval for the diabetic patients to 
develop complications.  
Thus diabetes imposes an economic burden on the national health 
policies, so early identification and modification of the risk factors would 
definitely help to reduce financial burden of the individual as well the 
country. This study was conducted with the aim to find the correlation of 
anthropometric measurements (height, weight, BMI, waist circumference, 
hip circumference, waist hip ratio, neck circumference) and  serum lipids 
with the severity of diabetic retinopathy.  
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 REVIEW OF LITERATURE 
The name “diabetes” is taken from the Greek word for a syphon; 
the sweet taste of urine of  the diabetes was recognized in the beginning 
of the first millennium, and the adjective “ mellitus ” meaning  (honeyed) 
was  given by Rollo in the 18th century. 
EPIDEMIOLOGY OF DIABETES MELLITUS: 
Current estimates suggest that two - thirds of those affected by  
diabetes live in lower and middle economic group countries.The 
pandemic growth of diabetes is due to transitional change in 
demographic, nutritional socioeconomic, lifestyle pattern. The 
International Diabetes Federation quotes that there are 285 million people 
with diabetes globally in 2010, and projects  that the absolute number will 
increase beyond  400 million in 2025. The percentage of diabetes will 
increase by 170% in the low and the middle income countries, compared 
to a 41% in developed countries. 
The prevalence of DM has increased from 30 million to 285 
million, since 15 years from 1995. Even though type 1 & type 2 diabetes 
increases widely across the globe, the incidence of type 2 diabetes 
mellitus has increased dramatically due to increasing over weight and 
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obesity, decreased physical activities, rapid urbanization and increase in 
number of older generation. Newly detected diabetics in 2010 were 1.6 
million. In 2010, the incidence of DM in United States of the America 
was estimated to be 26.9% in the age group greater than 65 years. The 
prevalence of diabetes was almost equal in both the sexes. It is estimated 
that in 2030 there will be more number of diabetics under the category of 
45 to 60 years. Much geographical difference is seen higher incidence of 
type 1 diabetes in Scandinavian countries and lower incidence seen in the 
Pacific zone. 
DIAGNOSIS OF DIABETES 
[1] 
 “Symptoms of diabetes and random blood glucose 
concentration -11.1 mmol/L or 200 mg/dL
a 
or 
 Fasting plasma glucose -7.0 mmol/L or 126 mg/dLb or 
 HbA1C > 6.5%c or 
 Two-hour plasma glucose -11.1 mmol/L or 200 mg/dL during 
an oral glucose tolerance test.
d
 
a
 Random - without regard to time since the last meal. 
b 
Fasting - no caloric intake for at least 8 h. 
 
c 
The test should be done in lab which is certified according to 
  A1C standards of the DCCT.  
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d 
The test should be done using a glucose load containing  75 g 
  anhydrous glucose, dissolved in water.
 
GLOBAL PREVALENCE OF DIABETES MELLITUS 
 
PREVALENCE OF DIABETES IN INDIA 
According to Indian Council of Medical Research – India Diabetes 
(ICMR-INDIAB)( 2008-2010) 
DIABETES 62.4 MILLION 
PRE DIABETES 77.4 MILLION 
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 Phase one  project of this study  included   3 States and 1 Union 
Territory,   representing   nearly 18.1 per cent of the nation's population. 
 
PREVALENCE OF  DIABETES IN INDIA 
MODIFIABLE BEHAVIOURAL RISK FACTOR 
Reduced physical activity 
 “Insufficient physical activity is defined as less than five times, 
thirty minutes of physical activity in a week, or less than 3 times, twenty 
minutes of vigorous activity in a week, or equivalent”.Reduced  physical 
activity which is the 4th major risk factor responsible for death. 
[7]
 
3.2million deaths each year were associated with insufficient physical 
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activity.
[7]
 Decreased physical activity has twenty to thirty % increased 
risk of mortality compared to those who carry out at least thirty minutes 
of  intense physical exercises in most days of the week. 
[8]
 
PREVALENCE OF PHYSICAL INACTIVITY GLOBALLY 
Gender Percentage 
ADULT MALE 28 
ADULT FEMALE 34 
 
Changing Unhealthy dietary habit 
1.7 million deaths globally are due to low fruit, vegetable 
consumption.
[9]
 Adequate intake of fruit and vegetables decreases the risk 
for cardiovascular diseases, stomach cancer and colorectal 
cancer.
[10,11]
WHO recommends  salt intake of less than 5 grams /person 
/day  for  prevention  of cardiovascular disease. 
[12]
 Risk of type 2 
diabetes is directly related with intake of saturated fat and trans-fat and 
inversely related  with polyunsaturated fat. 
[13]
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METABOLIC AND PHYSIOLOGICAL RISK FACTORS 
Raised blood pressure 
 “Increased blood pressure is defined as systolic blood pressure of 
greater or equal to 140 mmHg and or diastolic blood pressure of greater 
or equal to 90 mmHg”. Globally high blood pressure leads to 7.5 million 
deaths. Raised blood pressure is a risk factor for cerebrovascular accident 
and ischemic heart disease. 
[15]
 The risk of IHD increases twice for every 
raise of 20/10 mmHg of BP, starting as low as 115/75 mm hg. Across the 
world the prevalence of increased blood pressure in adults greater than or 
equal to 25 years was about 40% in 2008. The number of people with 
hypertension increased to 1 billion in 2008.
[16]
 Men had a higher 
prevalence than women 39% and 32% respectively. 
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Overweight and obesity 
Globally, every year about 2.8 million people die due to obesity 
and its complications. This leads to worse metabolic effects like increased 
BP, cholesterol, triglyceride and metabolic syndrome. Risks of IHD, 
cerebro  vascular accidents and diabetes mellitus increases with increase 
in BMI. Central adiposity is an important feature of the metabolic 
syndrome, which reflects that it has got close relationship between waist 
circumference and adiposity. 
 
High cholesterol 
High cholesterol levels increases the risk of heart disease and 
stroke.
[17]
 World wide, one third of IHD is associated with raised 
cholesterol. It accounts for 2.6 million deaths. 
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GENDER RAISED CHOLESTEROL (%) 
ADULT MALE 37 
ADULT FEMALE 40 
 
METABOLIC SYNDROME  
Also  called as syndrome X or insulin resistance syndrome. It is a 
group of metabolic abnormalities that serves as a risk factor for 
development of cardiovascular morbidities and mortalities and diabetes 
mellitus (DM). Criteria for  metabolic syndrome was given by World 
Health Organization. The major features of the metabolic syndrome 
include  
 central obesity, 
 hypertriglyceridemia,  
 low high-density lipoprotein (HDL) 
 cholesterol, 
 hyperglycemia, 
 and hypertension.  
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PATHOGENESIS OF METABOLIC SYNDROME 
Expanded adipose tissue mass releases free fatty acids (FFAs) in 
abundance. Increase in FFAs results in an abundant production of glucose 
and triglycerides and secretion of Very Low Density Lipoproteins 
(VLDLs) in liver, reductions in High-Density Lipoprotein (HDL) and an 
increased density of Low-Density Lipoproteins (LDLs). Insulin 
sensitivity is reduced in muscle by inhibiting insulin-mediated uptake of 
glucose, as a result glucose conversion to glycogen is reduced and 
increased accumulation of lipid in triglyceride (TG). Hyperinsulinemia 
occurs due to circulating high glucose, FFA and increase in pancreatic 
insulin secretion. 
Hyperinsulinemia will result in increased reabsorption of sodium in 
the proximal convoluted tubules of nephron which stimulates the activity 
of sympathetic nervous system results in hypertension, and in turn 
resulting in increased levels of circulating FFAs that superimposes on the 
pro inflammatory state and contributes to the insulin resistance through 
increased production of interleukin 6 and tumor necrosis factor  by 
adipocytes and monocytes. Prothrombotic state occurs due to increased 
hepatic production of fibrinogen and production of plasminogen activator 
inhibitor 1 (PAI-1) by the adipose tissue. The metabolic syndrome is 
associated with decreased production of the anti-inflammatory and 
insulin-sensitizing cytokine like   adiponectin 
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CAUSES AND CONSEQUENCES OF METABOLIC SYNDROME 
National Cholesterol Education Program criteria for metabolic 
syndrome 
Three or more of the following 
 Central obesity: Waist circumference greater than 102 cm in males 
and 88 cm in females. 
 Hypertriglyceridemia: Triglycerides greater than or equal to 150 
mg/dL or specific medication. 
 Low HDL  cholesterol less than 40 mg/dL and 50 mg/dL, 
respectively in male and female or specific medication. 
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 Hypertension: Blood pressure greater than or equal to 130 mm Hg 
of   systolic and 85 mm Hg of diastolic or specific medication. 
 Fasting plasma glucose greater than or equal to 100 mg/Dl or 
specific medication or previously diagnosed Type 2 diabetes.The 
risk factors are age, overweight, obesity, sedentary life style, 
coronary heart disease, diabetes, dyslipemia, and hypertension. 
INTERNATIONAL DIABETES FOUNDATION [IDF] CRITERIA –
SOUTH ASIANS FOR METABOLIC SYNDROME: 
Two or more of the following 
 Waist circumferences in adult males is ≥ 90 cm and ≥ 80 cm in 
females . Fasting triglycerides  greater than 150 mg/dL or specific 
medication. 
 HDL cholesterol  less than 40 mg/dL and 50 mg/dL for men and 
women, respectively, or specific medication. 
 Blood  pressure  greater than 130 mm Hg systolic or greater than 
85 mm Hg diastolic or previous diagnosis or specific medication. 
 Fasting plasma  glucose greater than 100 mg/dL or previously 
diagnosed Type 2 diabetes.  
 
 25 
PREVALANCE OF CENTRAL OBESITY IS COMMON IN 
ASIANS 
Compared with the Western population,Asian Indians have higher 
visceral fat higher upper body adiposity for a given BMI. Indians were 
found to have more upper body fat, which is valued by the waist-to-hip 
ratio (WHR) or waist circumference (WC), although they have lean body 
mass.
[19,20,2122]
 So, normal cut off value for each population varies, so this 
criteria does not hold good for all races. In northern region of India, the 
normal BMI was found to be 22 kg/m
2
 by  Dudeja et al. The WHO states 
that Asian Indian have lowers limits of BMI. Urban Indians have healthy 
BMI of 23 kg/m
2
, and the cut off values for waist circumference were 85 
cm for men and 80 cm for women and for waist hip ratio were 0.89 and 
0.81 for men and women. Hence, waist circumference is an useful index 
for upper-body adiposity. 
POPULATION PREVALENCE OF METABOLIC SYNDROME 
AND ITS COMPONENTS
[18] 
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Obesity and over weight 
Abnormal and enormous fat accumulation may impair the system 
of health. 
Body mass index (BMI) is based on weight-for-height which is 
commonly used for classification of overweight and obesity in adults. 
BMI=weight in kilograms /square of his height in meters (kg/m
2
) 
Normal body mass index  -18.5 to  24.9 kg/m
2
. 
In adults, when BMI -25 to 29.9 kg/m
2
 is termed as overweight. 
In adults, when   BMI is ≥ 30 kg/m2 is termed as obese. 
PREVALENCE OF OBESITY AND OVER WEIGHT 
In 2010 according to IASO/IOTF analysis, 1.0 billion adults were 
overweight, and 475 million were obese. In Asians, for obesity whose 
BMI   ≥ 28 kg/m2, then globally, number of adults who are considered 
obese will be > 600 million! 
According to IASO/IOTF, 200 million school going children 
belong to either overweight or obese category, among them 40-50 million 
are obese. 300 million women were obese and 200 million men were 
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obese. In 2010, overweight children under 5 years of age were 40 million. 
2.8 million adults die  due to obesity/year. Out of which 44% have the 
DM, 23% have IHD and 7% and 41% of  cancer. 
WORLD HEALTH ORGANISATION -2011, GLOBAL 
PREVALENCE  OF OBESITY. 
  OBESITY 40% (PACIFIC ISLANDS)  
  OBESITY 30-40%  
  OBESITY 20-30%  
 OBESITY 10-20% 
 < 10% 
 Globally, overweight and obesity causes more mortalities than 
underweight. 
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CAUSE OF OBESITY. 
 Worldwide, there is high consumption of energy-rich foods which 
are rich in salt, sugar  and fat and reduced  mineral, vitamins. Reduced 
exercises due to the highly sedentary nature, urbanization of rural areas 
sector, agriculture sector are the major cause of obesity. 
NUTRITION – DOUBLE EDGED WEAPON 
Low and middle economic group countries are affected much with 
overweight and obesity. Both under-nutrition and obesity exist together 
within the same country, community and the household. 
In developing   countries, children are more vulnerable to improper 
and poor intake of nutrition in pre-natal period, infancy and young 
childhood. Now a days, children are exposed to high-fatty food, high-
sugar, energy-dense, micronutrient-poor foods, which are low in 
cost.These type of diet patterns along with reduced physical activity, may 
result in rapid increase in obesity in children. 
GENETIC CHANGES IN OBESITY AND DIABETES 
Mutation in leptin – melano cortin signaling pathway, results in 
obesity. 2 -4 % of monogenetic obesity in children is due to mutations in 
melanocortin - 4 – receptor gene. Among the 20 genetic variants ,variants 
found  near the FTO and the MC4R gene seem to affect the body weight 
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in large proportion, resulting in extra 3 kilos compared to other genetic 
variant
[23]
, which encodes 2-oxoglutarate-dependent nucleic acid 
demethylase which is expressed in the brain and in the arcuate nucleus of 
the hypothalamus 
[24]
. Current assumption is that, there is a genetic failure 
of the pancreas to compensate for insulin resistance, characteristically 
resulting in obesity, and hence development of  Type 2 Diabetes
[25]
. 
Chronic over nutrition and hyper glycemia during pregnancy 
results in fetal hyper insulinemia, hyper leptinemia and hyper 
cortisolemia. These  changes leads to mal programming and hence mal 
functioning of hypothalamic centers which controls the homeostasis of 
energy and metabolism, which increases the lifetime risk for obesity and 
T2DM
[26]
. Gut hormones, signals the gastro intestinal nervous system and 
induces the complex integration of the central nervous system signalling 
namely the anorexigenic leptin – melanocortin link and the orexigenic 
NPY – AgRP pathway, according to the dietary intake of the individual. 
LINKS BETWEEN OBESITY AND TYPE 2 DIABETES 
INSULIN RESISTANCE AND OBESITY: 
              The initial hypothesis which relates obesity and T2DM is 
“glucose – fatty acid cycle” where exists a competition between oxidation 
of glucose and fatty acid in the muscle
[27]
. Increased amount of non - 
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esterified fatty acids from increasing adipose tissue competes with the 
utilisation of glucose especially in muscle, where glucose is  oxidised. 
Inhibition of glycolytic enzymes like pyruvate dehydrogenase, 
hexokinase, phosphofructokinase take place. Recent studies suggest that 
there are more intra myocellular lipid accumulation which also increases 
the insulin – resistant state. Hence, intra muscular accumulation of neutral 
fatty acids, and its metabolites such as ceramide, diacylglycerol and fatty 
acyl coenzyme A (CoA ) take place disturbing the insulin action by an 
activation of a serine –threonine  kinase cascade resulting in 
phosphorylation of Insulin Receptor Substrate-1 (IRS - 1) and IRS – 2. [28]  
 
OVER NUTRITION AND SYSTEMIC INSULIN RESISTANCE 
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LIPIDS AND ΒETA - CELL FUNCTION:  
Chronic exposure of fatty acids results in impaired insulin secretion 
and decrease in insulin biosynthesis
[29]
. Increased expression of 
uncoupling protein (UCP - 2) results in impaired insulin secretion. 
Insulin resistant offspring of parents with T2DM have features of 
impaired mitochondrial function 
[30]
. Obese individuals have very smaller 
mitochondria who have reduced bioenergetic capacity when compared 
with lean controls. 
[31] 
SECRETORY FUNCTION OF ADIPOSE TISSUE . 
TNF - α is  a cytokine, expressed in adipose tissue [32]  leading to 
suppression of GLUT 4, lipoprotein lipase expression, increase in 
lipolysis 
[33]
, activation of NF - κB leading to increased pro-inflammatory 
cytokines like Interleukin 6 (IL - 6), IL-8 and monocyte chemotactic 
protein 1 (MCP ). It reduces the expression of adiponectin, which exerts 
direct antidiabetic and the anti-atherosclerotic actions. It also stimulates 
the phosphorylation of IRS - 1 at the serine residue 307 there by 
inhibiting the transduction of the insulin signal 
[34]
. Prodiabetic action 
include activation of plasminogen activator inhibitor 1 (PAI - 1), lipid 
metabolites such as ceramide.  
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Retinol - binding protein 4 (RBP - 4) leads to insulin resistance via 
reduced PI 3 and anti - inflammatory properties like adiponectin, IL -
1receptor antagonist and IL – 10, adiponectin. Adiponectin levels are 
inversely associated with BMI and that low level results in the 
development of T2DM 
[35,36]
. It  has an antidiabetic and anti – 
atherosclerotic activity which increases the oxidation of the fatty acid 
through an AMP - activated protein kinase  pathway. 
INFLAMMATORY RESPONSE IN ADIPOSE TISSUE  
Inflammatory activity in adipose tissue is through the activation of 
the c - Jun N – terminal  kinase (JNK) and IKK β – NF - κ B, which 
further stimulates  cytokines such as TNF - α and IL – 6.. In obesity, JNK 
activity  is elevated in liver and muscle as in the adipose tissue. IKK β 
stimulates the production of many pro inflammatory mediators including 
TNF - α and IL-6  the activation of NF - κ B pathways [37]. The functional 
capacity of the endoplasmic reticulum is overloaded in obesity and leads 
to activation of the inflammatory signalling pathways. 
OXIDATIVE STRESS  
Increased production of reactive oxygen species (ROS) occurs in 
adipose tissue with increased expression of NADPH oxidase and reduced 
expression of antioxidative enzymes.  
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HYPOXIA IN ADIPOSE TISSUE 
Hypoxic response genes are hypoxia-inducible factor 1α (HIF-1α). 
Vascular Endothelial Growth Factor (VEGF) and heme  oxygenase. It 
leads to reduced mitochondrial respiration and increase in lactate 
production. It also reduces the expression of adiponectin. 
BODY FAT DISTRIBUTION IN OBESITY 
Abdominal type of body fat distribution leads to increased risk of 
diabetes and cardiovascular complications. Intra - abdominal fat is 
lipolytically more active than adipocytes in the sub cutaneous tissue and 
with increased accumulation of lymphocytes and macrophages, indicates 
the proinflammatory activity. Visceral adipose tissue has greater blood 
vessel and nerve density with higher metabolic activity which drains into 
the portal vein. Liver is directly exposed to fatty acids and proteins which 
stimulates insulin resistance in the liver. The largest endocrine gland is 
adipose tissue as it produces free fatty acids, growth factors, hormones, 
and cytokines such as VEGF, HGF, IGF-1, leptin, angiogenin, IL-6, 
TNF-alpha adiponectin, resistin and angiopoietins. 
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ADIPOGENESIS AND ANGIOGENESIS 
Brown adipose tissue has a very high energy expenditure, but it 
remains functionally silent in obesity. Its thermogenic activity is due to  
high perfusion of blood in order to provide O2 and substrates and to 
dissipate energy in the form of heat. Hence, angiogenesis is very much 
necessary for hyperplasia of brown adipose tissue, which depends on the 
quick activation of mitosis of precursor cells of brown adipose tissue to 
generate new capillaries. White adipose tissue can be transformed into 
brown adipose tissue on chronic exposure to cold. Regression of certain 
capillary networks leads to transformation of brown adipose tissue into 
white adipose tissue. 
 
ADIPOSE TISSUE MODULATING ANGIOGENESIS 
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INTERACTION  BETWEEN ADIPOCYTES AND ENDOTHELIAL  
CELLS 
Endothelial cells of the capillaries interact with the fat tissue by 
means of paracrine signals through ECM, and direct cell-cell 
communication 
[39,40,41]
. Preadipocytes of human and endothelial cells of 
the capillaries express  plasminogen activator inhibitor 1 and αvβ3 
integrin, which helps in  preadipocyte migration towards the developing 
capillaries to enable the  coordination of the development of  both 
preadipocytes and the capillary  endothelial tissues at the same 
place.
[47]
Adipose tissue produces Matrix MetalloProteinases like MMP-2 
and-9,and affects the development of  microvessel and preadipocyte 
differentiation  by changing the extra cellular matrix 
[44]
. It is able to 
generate the matrix bound vascular endothelial growth factor and there by 
stimulates proliferation of blood vessels 
[45]
. Endogenous matrix metallo 
proteinases stimulate and maintain proliferation of blood vessels
[46,47]
. 
High-calorie diet induced obesity is observed in matrix metallo 
proteinase-3–deficiency. The density of blood vessels in adipose tissue 
was found to be increased in those mice which were devoid of this 
particular gene, implying that matrix metallo proteinase -3 alters 
proliferation of blood vessels in adipose tissue 
[48]
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Tissue inhibitor metallo proteinase and matrix metalloproteins has 
a major role in angiogenesis. In expanding adipose tissue, hypoxia is 
found to be one of the major determinant factor for growth of vessels. As 
a result of hypoxia,adipose tissues produces  hypoxia inducible factor 1a– 
angiogenic factors such as VEGF, leptin, TNF-α, and PAI-1, which helps 
in the maintenance and regulation of angiogenesis and adipogenesis. 
Growing adipocytes produce numerous factors which alters the 
angiogenesis which include leptin, VEGF, VEGF-C, HGF, IGF FGF-2, 
TGF-β, TNF-α, placental growth factor (PlGF, resistin, heparin-binding 
epidermal growth factor, neuropeptide .Macrophages which are activated  
produce more potent angiogenic factors like as TNF-α, VEGF, IL-1b, IL-
6, and IL-8  and FGF.    
LEPTIN  
It is hormone derived from adipose tissues. It governs intake of 
food and homeostasis of energy. Any impairment in the functioning of 
leptin  results  in severe obesity, infertility and diabetes. It is an important 
factor that influences the proliferation of blood vessels. Endothelial cells 
express leptin receptor (OB-Rb) – which has helped in discovery of  
angiogenic activity of leptin
[50]
.In endothelial cells, leptin interacts with 
its OB-Rb receptor which leadto stimulation  of the Stat3 pathway and 
enhances the activity of its binding .  
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LEPTIN REGULATING ANGIOGENESIS 
Apart from the angiogenic activity of leptin, it also stimulates the 
expression of  VEGF mRNA through the regulation of the Jak/Stat3 
signaling pathway. Leptin helps  in  induction  of  MMP-2 and MMP-9 
activity, which indirectly helps in angiogenesis. During the hypoxic 
conditions, the  ratios of VEGF and leptin are elevated. Thus it has an 
important  role in the development of vasculature and  its  remodelling by 
altering the  production  levels of  angiogenic factors. 
Leptin, effectively induces the activity of endothelial NOS  thereby  
increasing the vasodilation and also blood supply in the fatty tissue 
[51,52]
. 
Thus the rapidly developing adipose tissue has many capillaries  that are 
 
 38 
fenestrated which is essential for permeability of blood vessels. 
Neuropeptide Y  is another example of peptide which acts as both 
endocrine and paracrine factor there by controlling the adipogenesis and 
obesity. 
Resistin is  a specific adipokine, which  is defined “as a novel  
angiogenic factor which  directly stimulates the proliferation of 
endothelial cells, migration, and the  tube formation
[53]”.  
Insulin Growth Factor-1 is a potent  angiogenic  factor for 
numerous  cells  and  plays a critical role in regulating the integrity of 
vessels in the fatty tissue. IL-8 is another pivotal factor for adipocytes  for 
maintaining the regulation of angiogenesis. Angiogenic factors includes 
VEGF-B, VEGF-C, and angiogenin that have been positively correlated 
with body mass index. 
[54,55]
  
Adiponectin, an angiogenesis inhibitor, accumulates in the 
circulation of lean people and safe guards against the disease like diabetes 
and atherosclerosis. 
[56]
Adiponectin levels in the blood have a negative 
relationship with BMI and are reduced in obese humans, suggesting a 
negative role of adiponectin  in the  regulation of adipogenesis. 
[57]
It 
inhibits the proliferation of endothelial cell and its survival by the 
activation of caspase mediated  endothelial cell apoptosis
[58]
. 
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Angiogenesis inhibitors which are produced endogenously - endostatin, 
thrombospondin 1 (TSP-1), soluble VEGFR-2 are at increased  levels in 
obese subjects when compared to lean individuals 
[59,60]
. PlGF, indirectly 
inhibits the angiogenesis of adipose tissue by negatively modulating the 
angiogenic activity of VEGF. 
TNP-470 in obese  mice, results in a reversible weight reduction 
and also cause reduction of fatty tissue  without significantly affecting the 
food intakes. Other anti angiogenic factors like as angiostatin and 
endostatin  target the  cells of endothelium  and not the other cell types, 
the anti-obesity activity of this sort of inhibitors is achieved through their 
antiangiogenic activity. Remarkable vascular remodeling is achieved by 
the angiogenesis inhibitor by stimulation  of apoptotic cells and  
decreasing the endothelial cells which are proliferating vigorously. 
Interesting finding is that these anti  angiogenic factor like TNP-470 also  
increases the  sensitivity of insulin in obese animals, implying that these 
angiogeneic inhibitor  normalizes  the  sensitivity of insulin  and  also 
prevents the development of type II diabetes mellitus. 
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PATHOGENESIS OF MICRO VASCULAR COMPLICATION OF 
DIABETES: 
1. By the polyol pathway, there is increased  flux of glucose and other 
sugars. 
2. Increased advanced glycated  end products (AGEs), intracellularly. 
3. More production of the receptor for Advanced Glycated End 
products (RAGE) and its activating ligands. 
4. Activation of protein kinase C (PKC) isoforms. 
5. Overactivity of hexosamine pathway and a unifying hypothesis for 
the pathogenesis of diabetic complications  is overproduction of the 
reactive oxygen species (ROS) superoxide by mitochondria . 
When  concentration of glucose is normal, aldose reductase 
decreases the toxic aldehydes which is  generated by reactive oxygen 
species (ROS) to inactive alcohol but not in hyperglycemia, it can also 
reduce glucose to sorbitol which  induces the  osmotic stress by 
decreasing the cytosolic Na/K 
+
 - ATPase activity,increased cytosolic 
NADH/NAD.
+.
 Intracellular accumulation of sorbitol  results in osmotic 
damage in diabetic vessels. Increased sorbitol amount alters  the  redox 
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potential,  elevates osmolality of cells, produces  more  reactive oxygen 
species,  thereby causing  cellular dysfunction. 
 
MAJOR PATHWAYS OF HYPERGLYCEMIC DAMAGE 
INCREASED INTRACELLULAR  ADVANCED GLYCATED END 
PRODUCTS 
AGEs are formed by the reaction of glucose with proteins and, to 
nucleic acids. These reactions are reversible initially and give rise to early 
glycation products. Eventually they become irreversible which impair the 
structural and enzymatic functions of the proteins. AGEs are found in 
increased amounts in extracellular structures of diabetic retinal vessels 
[74]
 
and renal glomeruli. 
[75,76,77] 
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AGEs can arise intracellularly by the oxidation of glucose to 
glyoxal 
[78]
, the conversion  of an Amadori product  in to the 3 
deoxyglucosone, or the fragmentation of glyceraldehyde - 3 - phosphate 
to yield methylglyoxal 
[79]
. All these intracellular dicarbonyls react with 
uncharged amino groups of  intracellular proteins  to form AGEs. The 
major intracellular AGE precursor is Methylglyoxal
[80,81] 
   
 
ROLE OF AGE IN MODULATING INTRACELLULAR AND EXTRA 
CELLULAR PROTEINS AND ITS INTERACTION OF REACTIVE OXYGEN 
SPECIES 
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INTRACELLULAR EFFECTS OF AGEs 
AGE precursors can damage cells by 3 process:  
1. AGE modifies the intracellular proteins which will have varied 
 function. 
2. Extracellular matrix components  are modified by AGE precursors  
which interacts differently  with  other components in the matrix . 
3. Plasma proteins  are modified by advanced glycated end products 
precursors and they  bind to advanced glycated end product 
receptors on cells like macrophage and stimulates the  production 
of ROS, which further  activates the transcription factor, nuclear 
factor κ B (NF κ B), resulting in numerous  pathologic changes in 
gene expression. 
[82]
AGE modification of intracellular protein is  
involved in diabetic retinopath. In diabetes, retinal capillary 
formation is maintained by complex  interactions among pro- and 
anti- angiogenic factors 
[83,84]
, including angiopoietin- 2 (Ang- 
2).
[85]
   
EFFECTS OF AGES ON EXTRACELLULAR MATRIX 
AGE production  changes  the functional activities  of many  
matrix molecules like collagen which along with AGEs were shown to 
form covalent intermolecular bonds which is mediated by H2O2 
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production
[86]
 ,glycated type I collagen cross - linking results in expansion 
of molecular packing 
[87]
, glycated type IV collagen  inhibits the normal 
lateral association of the  molecules. AGE formation on laminin prevents 
it from self - assembling into a polymer. AGE  induced cross - links alter 
the  tissue function, especially in blood vessels also reduces the  elasticity 
in arteries in diabetes. AGEs induced cross-linked proteins  like collagen, 
extracellular matrix proteins,  aggravates   the process of  atherosclerosis,  
stimulates  the dysfunction  of  glomerulus, decreases the synthesis of 
nitric oxide, accelerates the dysfunction of  endothelium, and composition 
of matrix  is altered. The serum level of advanced glycated end products 
accumulate when  GFR  declines. 
PATHOLOGICAL CONSEQUENCES OF PROTEIN KINASE 
ACTIVATION 
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Hyperglycemia raises the production  of diacylglycerol which leads 
to stimulation  of Protein Kinase C (PKC ) which changes and modulates  
the transcription of genes for fibronectin, type IV collagen, contractile 
proteins 
In diabetic proliferative retinopathy , Vascular Endothelial Growth 
Factor A (VEGF-A)  increases  and its level decreases after laser 
photocoagulation. 
DIABETIC RETINOPATHY: 
 “Diabetic retinopathy is a sight-threatening chronic micro vascular 
complication”. Diabetic retinopathy leads to a progressive changes  in the 
retinal micro vessels  which is gradual, resulting in  nonperfusion of some 
areas in retina, increased vascular permeability leading to macular edema, 
abnormal  proliferation of retinal vessels. 
In developed countries of the world, diabetic retinopathy is the 
leading cause of new-onset blindness in working-aged person. More than 
90% of vision loss occuring due to proliferative diabetic retinopathy can 
be prevented. 
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PREVALANCE IN WORLD 
An international study states that the duration of diabetes, poor 
glycemic and blood pressure control are strongly associated with a higher 
prevalence of diabetic retinopathy. The research was presented in 2011 
Annual Meeting of the Association for Research in Vision and 
Ophthalmology. 
DISEASE 
PREVALANCE IN 
MILLIONS (2010) 
2030 
DIABETIC RETINOPATHY 100.8 154.9 
PROLIFERATIVE DR 20.6 31.7 
DIABETIC MACULAR EDEMA 21.3 32.8 
VISION THREATENING DR 33.4 51.3 
 
World Health Organization states that the combined  diabetic 
population of India and China is 52.4 million. This data will increase to 
121.8 million and thrice of current world prevalence.  Two large Indian 
clinical study were performed and announced the prevalence of diabetic 
retinopathy in southern region of India as 34.1% and 37%. Prevalence in 
urban South Indians  was 17.6%, which was much lower than in other  
groups. Out of   31.7 million diabetic people who live in India, greater  
than 5.6 million subjects suffer from diabetic retinopathy.  
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MODIFIABLE RISK FACTORS FOR DIABETIC RETINOPATHY 
BLOOD GLUCOSE: 
Tight blood glucose control decreases the risk of new onset 
diabetic retinopathy  and decreases  the progression of previously existing  
DR in patients with type 1 diabetes mellitus (T1DM) according to the 
study conducted by DCCT.
[61]
The UK Prospective Diabetes Study 
(UKPDS) 
[62]
 concluded the tight blood glucose control decreased the risk 
of new onset diabetic retinopathy  and slows down  the progression of 
previously occurred  diabetic retinopathy  in T2DM. 
SYSTEMIC HYPERTENSION 
Tight control of  blood pressure resulted in reduction of new onset 
DR and slowed the progression of already existing  DR. 
[63,64]
 . 
CORRELATION OF DIABETIC RETINOPATHY WITH 
FASTING. POST PRANDIAL AND HBA1c 
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SERUM LIPIDS 
Raised  serum lipids were related with exudates at macula and 
moderate  loss of vision .
[65,66]
 . 
Smoking 
Smoking may be a risk factor in the progression of DR in T1DM as 
detailed  by Muhlhauser et al 
[67]
 and Karamanos et al. 
[68]
 
NON - MODIFI ABLE RISK F ACTORS 
Duration 
Non - modifiable factor that determines the progression of DR is 
the duration of diabetes.
[69]
 
Age 
Wisconsin Epidemiological Study 
[70,71]
stated that people who  
suffered from diabetes for 10 years,in the age less than 30 years, the 
grading and the severity  was related with the older  age of diagnosis 
where as when the age at diagnosis was 30 years or more,  retinopathy 
severity was  associated with  younger age at diagnosis. 
Genetic predisposition 
Monozygotic  twins with diabetes have a strong familial  clustering 
of DR. 
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Ethnicity 
There was higher prevalence of DR in Latin Americans (36%) and 
African - Americans (29%) than for whites of Northern European 
ancestry (22%).
[73]
  
 
 
NEURO DEGENERATION 
LEADS TO INCREASED 
GROWTH FACTORS,LOSS 
OF PROBARRIER 
FACTORS,AGGRAVATES 
VASCULAR DAMAGE 
ULTIMATELY LEADING TO 
IMPAIRED VISION 
NORMAL BLOOD BRAIN 
BARRIER 
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PATHOLOGICAL  PHYSIOLOGICAL CHANGES  IN DIABETIC 
RETINOPATHY 
Diabetic retinopahy is microvasculopathy in which small blood 
vessels & retinal cells  are damaged due to hyperglycemia  
Cellular  damage   
Is due to intracellular sorbitol accumulation, oxidative   oxygen  
free radical excess induced oxidative stress , accumulation of AGE’S and 
abnormal activation of protein kinase C isoforms.  
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Capillaropathy 
Is  due to death of pericytes , loss of vascular smooth muscle cells, 
thickening of BM  and proliferation of vascular endothelial cells. 
Rheological  changes such as abnormalities of RBC’S  and  WBC’S, 
increased platelet stickiness, and  plasma viscosity may also contribute. 
Capillaropathy  manifests with leakage and occlusion. 
Neovascularization 
It  is due to  capillary non-perfusion  leading on to  retinal hypoxia 
which results in  neovascularization extending preretinally (PDR) and 
intraretinally; and development of intraretinal microvascular 
abnormalities (IRMA) are shunts that run within the retina from arterioles 
to venules. Neovascularisation   is  due to  imbalance between the  
angiogenic(VEGF,PDGF,HGF) and anti-angiogenic (angiostatin , 
endostatin pigment epithelium-derived factor)  . 
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Screening for diabetic retinopathy 
All these features causes occlusion of microvessel of retina.  In 
1968, World Health Organization (WHO) [34] first  introduced the  
screening tests.  
SCHEDULE FOR OPTHALMIC EXAMINATION IN DIABETES  
GROUP FIRST EXAMINATION 
ROUTINE 
FOLLOW-UP 
Type 1 diabetes Within 5 years after diagnosis 
of diabetes once patient is age 
10 years or older 
Yearly 
Type 2 diabetes At time of diagnosis of diabetes Yearly 
Pregnancy in 
preexisting diabetes 
Prior to conception and during 
first trimester. Counsel on the 
risk of development and/or 
progression of retinopathy-. 
Close follow-up 
throughout 
pregnancy and 
for one year 
postpartum. 
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NORMAL PERSON  AND PATIENT WITH DIABETIC 
RETINOPATHY 
 
 CLASSIFICATIONOF DIABETIC RETINOPATHY
103
: 
Diabetic retinopathy is broadly classified in to two categories 
namely   
1. Non proliferative Diabetic Retinopathy  
2. Proliferative Diabetic Retinopathy 
  
SYMPTOMS OF DIABETIC RETINOPATHY 
• Blurred vision 
• Floaters 
• Fluctuating vision 
• Distorted vision  
• Dark areas in the vision 
• Poor night vision 
• Impaired color vision 
• Partial or total loss of vision  
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Nonproliferative Diabetic Retinopathy (NPDR) 
Very mild NPDR: 
Microaneurysms only 
Mild NPDR 
Any or all of  : 
 microaneurysms,  
 retinal haemorrhages, 
 exudates,  
 cotton wool spots, up to the level of moderate NPDR.  
Moderate NPDR: 
Any of the following: 
 Severe retinal haemorrhages in 1–3 quadrants or mild intraretinal 
microvascular abnormalities (IRMA), 
 Significant venous beading can be present in no more than 1 
quadrant, 
 Cotton wool spots commonly present. 
Severe NPDR: 
One or more of: 
 Severe hemorrhages in all 4 quadrants 
 Significant venous beading in 2 or more quadrants 
 Moderate IRMA in one or more quadrant 
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Very severe NPDR: 
Any two or more of criteria for severe NPDR 
PROLIFERATIVE DIABETIC RETINOPATHY (PDR) 
Early PDR: 
New vessels 
 Criteria not met for high-risk PDR 
High-risk PDR: 
 Neovascularization of the disk ≥ 1/3-1/2 disk area   OR 
 Neovascularization of the disk and vitreous or preretinal 
 hemorrhage  OR 
 Neovascularization elsewhere ≥ 1/2 disk area AND vitreous or 
 pretretinal  hemorrhage 
Severe PDR: 
 Posterior fundus obscured by preretinal or vitreous hemorrhage  
OR 
 Center of macula detached 
 
 56 
CLINICALLY SIGNIFICANT MACULAR EDEMA (CSME) 
 Thickening of the retina ≤500µm from the center of the macula   
OR 
 Hard exudates and adjacent retinal thickening ≤500µm from 
 macular  center  OR 
 Zone of retinal thickening at least 1 disc area in size located ≤1 
disc diameter from the center of the macula. 
Microaneurysms –  It  is s a red spot of less than 125 micro meter 
• Small retinal hemorrhages – It is  a red spot, with irregular margins  
with  or without  uneven density, surrounding a microaneurysm. 
Hard exudates: 
It is  a small white or yellow coloured  deposits with  sharp 
margins,  seen in the  in the superficial, outer  layers of the retina. 
Cotton wool spots 
It is otherwise called as soft exudate. It is white fluffy opaque in 
nature. It occurs  due to stasis of axoplasm in the nerve fiber layer caused 
by arteriolar occlusion. 
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Neovascularization of the disc : new vessels on or within 1 
disc diameter of disc margin. 
Neovascularization elsewhere: new vessels elsewhere in the 
retina outside of disc and more than 1 disc diameter from disc 
margin 
Diabetic retinopathy can be easily identified by complete and 
thorough eye examination. 
Retinal imaging 
Digital colour retinal photography is used to detect the lesions in 
retina. 
Fundus fluorescein angiography 
Sodium fluorescein injection is given rapidly into the arm and the 
fluorescence of the dye, enables photographs to be taken as it appears in 
the retina. The fluorescein dye cause side effects like nausea, vomiting, 
occasional syncope, skin rashes and itching. 
Optical coherence tomography 
It  interprets the  reflected optical waves using interferometry. 
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Ultrasound B scan examination 
In cases of vitreous hemorrhage the presence or absence of a retinal 
detachment, where retinal view is obscured, can be examined. 
Perimetry 
 It  helps in the  assessment of the visual field. 
TREATMENT OF DIABETIC RETINOPATHY 
PRIMARY PREVENTION 
Strict glycemic and blood pressure control 
SECONDARY PREVENTION 
       Annual eye examination 
TERITIARY PREVENTION 
ARGON LASER PHOTO COAGULATION 
All eyes with clinically significant macular edema should be 
considered for Argon  laser photocoagulation irrespective of their visual 
loss which is the primary therapeutic modality. 
It helps in sealing of leaking micro vessels of retina and decreasing 
the oxygen demand in retina especially for clinically significant macula 
edema and high risk proliferative retinopathy 
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OTHER TREATMENT MODALITY 
Other lasers: 
 Frequency-doubled Nd:YAG laser offers the potential of a less 
destructive retinal effect than argon.  
The ‘Pattern Scan Laser’ (Pascal) uses frequency-doubled 
micropulse YAG in single shot mode or upto  56 shots applied in 
less than a second. 
 Micropulse diode laser in which short duration (microseconds) 
burns are applied to the RPE without significantly affecting the 
outer retina and choriocapillaris. 
Anti –VEGF agents: 
Intravitreal injection of 0.5 mg ranibizumab, initially given 
monthly for 3 months, these agents will  play an prominent role in the 
treatment of diabetic retinopathy in near future . 
INTRAVITREAL TRIAMCINOLONE. 
This can also be used with substantial results. 
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PARS PLANA VITRECTOMY 
It is indicated in patients with 
 Severe persistent vitreous haemorrhage 
 Progressive tractional RD 
 Combined tractional and rhegmatogenous RD  
 Premacular subhyaloid haemorrhage 
LIPID-LOWERING DRUGS  
It may reduce the requirement for laser treatment, and studies are 
ongoing. 
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AIM OF THE STUDY 
PRIMARY OUTCOME: 
To study the correlation of anthropometric measurements with the 
severity of diabetic retinopathy. 
SECONDARY OUTCOME: 
To study the correlation of anthropometric measurements with 
occult nephropathy. 
To study the correlation of anthropometric measurements with 
serum lipids. 
 Place of study: Government  Royapettah  Hospital, Chennai - 14 .   
 Collaborative department : Department of Diabetology and 
Department of Ophthalmology, Government Royapettah Hospital  .    
 Study design: Cross sectional ,observational study. 
 Sample size :100. 
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INCLUSION CRITERIA  
  Type 1 and type 2 diabetics of all age groups were included. 
EXCLUSION CRITERIA 
Patients with following disease were excluded from the study. 
 Hypertension 
 Chronic kidney disease 
 Thyromegaly 
 Cervical lymph node enlargement 
 Neck surgeries 
 Other retinopathies 
 Cataract and ocular surgeries 
 
 64 
 
 
 
 
 
 
MATERIALS AND 
METHODS 
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METHODS AND STATISTICAL ANALYSIS 
This was a clinical study of  patients with  type 1 and type 2 
diabetes  attending Government Royapettah Hospital. Ethical committee 
clearance was obtained from the ethical committee board of Kilpauk 
Medical College. Each individual signed a consent form after explaining 
the  methodology and study purpose. 
Anthropometric measurements: 
Anthropometric measurements were measured using standard 
methods: 
Weight was measured after removing slippers, and after emptying 
bladder using standard weighing machine. Height was measured after 
removing the slippers  with stadiometer. Body mass index was calculated 
by computing the values in the formula BMI= weight in kilogram / height 
in metre squares. Body mass index was classified according to World 
Health Organisation criteria that is  under weight  normal weight 18- 
24.9%, over weight – 25-29.9% , obese > 30%. Waist circumference  was 
measured  using tape measurements at midpoint between costal margin 
and iliac crest. Hip circumference was measured  at the level of greater 
trochanter and waist hip ratio were measured by dividing waist 
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circumference and hip circumference. Neck circumference was measured 
using inch tape to nearest 1 mm  taken in horizontal plane below the 
larynx  perpendicular to the long axis of neck with head straight. 
Blood pressure was measured was recorded twice and average of 
two measurements were taken in to account. Blood samples were with 
drawn and serum cholesterol, triglycerides, fasting and post prandial 
blood sugar measured, and fundus examination was done after dilation 
with 1 % tropicamide and fundus grading was done by the 
ophthalmologist with Heine
®
 mini ophthalmoscope . Diabetic retinopathy 
was graded into non proliferative (mild, moderate, severe, very severe) or 
proliferative (early, high risk, severe).  
Statistical analysis were performed  using Microsoft excel. After 
acquiring the complete set of data and preparing the master chart,  with 
the help of statistician, data was analysed with Statistics Products 
Services Solutions (SPSS)
®
 software for windows .Pearson correlation 
and Chi square test are used for finding the association of anthropometric 
parameters with diabetic retinopathy. p vaue <0.05 was considered to be  
significant and p value < 0.01  was very significant. 
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OBSERVATION AND ANALYSIS 
NO. OF PATIENTS IN THE STUDY MALE AND FEMALE 
 Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid F 50 50.0 50.0 50.0 
M 50 50.0 50.0 100.0 
Total 100 100.0 100.0  
 
This frequency table says that equal numbers of male and female  
diabetic  patients participated  in this study .  
CHART :1 
male
female
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TYPE OF DIABETES IN THE STUDY POPULATION 
 Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid 
1 9 9.0 9.0 9.0 
2 91 91.0 91.0 100.0 
Total 100 100.0 100.0  
 
The number of parcipatants in type 1 diabetes is 9 and in type 2 the 
number is 91. 
CHART 2 
0
20
40
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80
100
TYPE 1 TYPE 2
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NUMBER
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DESCRIPTIVE ANALYSIS 
 N Range 
Minimu
m 
Maximu
m 
Mean 
Std. 
Deviation 
AGE 100 49 19 68 51.10 9.380 
DURATION 100 12 3 15 7.57 2.524 
SBP 100 46 116 162 138.35 10.586 
DBP 100 34 68 102 82.80 7.407 
WT 100 71 35 106 67.66 12.005 
HT 100 31.5 142.5 174.0 158.470 6.5958 
BMI 100 23.06 17.11 40.17 26.9077 4.20264 
WAIST 100 44 70 114 90.31 9.540 
HIP 100 42 82 124 103.33 8.923 
W/H 100 .28 .70 .98 .8691 .05659 
NECK C 100 19.0 27.0 46.0 34.619 2.7067 
FBS 100 257 85 342 203.17 55.793 
PPBS 100 290 108 398 257.65 59.896 
URINE PCR 100 .63 .01 .64 .2947 .13675 
CHOLESTEROL 100 224 154 378 234.10 43.145 
TGL 100 244 113 357 167.69 38.199 
Valid N (listwise) 100      
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Descriptive variables in the study  were age, sex, duration of 
diabetes, blood pressure, weight, height, body mass index, waist 
circumference, hip circumference, waist hip ratio, neck circumference, 
fasting blood sugar, post prandial blood sugar, urine spot  protein  
creatine  ratio, cholesterol, triglycerides. 
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CORRELATION 
 BMI GRADE 
W/H NECK C DURATION 
BMI Pearson 
Correlation 
1 .235
*
 .213
*
 .466
**
 .354
**
 
Sig. (2-tailed)  .019 .034 .000 .000 
N 100 100 100 100 100 
GRADE Pearson 
Correlation 
.235
*
 1 .245
*
 .214
*
 .507
**
 
Sig. (2-tailed) .019  .014 .032 .000 
N 100 100 100 100 100 
W/H Pearson 
Correlation 
.213
*
 .245
*
 1 .178 .144 
Sig. (2-tailed) .034 .014 
 
.077 .154 
N 100 100 100 100 100 
NECK C Pearson 
Correlation 
.466
**
 .214
*
 .178 1 .231
*
 
Sig. (2-tailed) .000 .032 .077 
 
.021 
N 100 100 100 100 100 
DURAT
ION 
Pearson 
Correlation 
.354
**
 .507
**
 .144 .231
*
 1 
Sig. (2-tailed) .000 .000 .154 .021 
 
N 100 100 100 100 100 
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BMI_INTERVAL 
 Frequency Percent 
Valid 
Percent 
Cumula
tive 
Percent 
Valid Under 
weight 
1 1.0 1.0 1.0 
Normal 34 34.0 34.0 35.0 
overweight 46 46.0 46.0 81.0 
obese 19 19.0 19.0 100.0 
Total 100 100.0 100.0  
 
 
BMI is classified according to various class intervals .i. e 1) under 
weight -<18 % 2) normal weight 18- 24.9% , 3) over weight – 25-29.9% 
,4) obese > 30%. 
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RETINOPATHY GRADE VS BMI 
Pearson Correlation .235
*
 
Sig. (2-tailed) .019 
N 100 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
 
There is a positive correlation between retinopathy grade and body 
mass index with a significant probability value of 0.019. 
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RETINOPATHY GRADE VS NECK CIRCUMFERENCE 
NECK C Pearson Correlation .466
**
 
Sig. (2-tailed) .000 
N 100 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
 
There is statistical  significant  correlation  of neck circumference 
with  retinopathy grade. 
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FUNDUS GRADE VS  WAIST HIP RATIO 
W/H Peoarson Correlation .245
*
 
Sig. (2-tailed) .014 
N 100 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
 
This study shows very significant correlation of Waist hip ratio  
with retinopathy grade with a p value of 0.014. 
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SECONDARY OUTCOME: 
Correlation of neck circumference and BMI vs Fundus grade, 
Waist hip ratio, duration of diabetes. 
Correlations 
 NECK C DURATION 
Spearman's 
rho 
BMI Correlation Coefficient .456
**
 .323
**
 
Sig. (2-tailed) .000 .001 
N 100 100 
GRADE Correlation Coefficient .494
**
 .409
**
 
Sig. (2-tailed) .000 .000 
N 100 100 
W/H Correlation Coefficient .213
*
 .215
*
 
Sig. (2-tailed) .034 .032 
N 100 100 
NECK C Correlation Coefficient 1.000 .246
*
 
Sig. (2-tailed) . .014 
N 100 100 
DURATI
ON 
Correlation Coefficient .246
*
 1.000 
Sig. (2-tailed) .014 . 
N 100 100 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
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BMI VS NECK CIRCUMFERENCE 
BMI Pearson Correlation .466
**
 
Sig. (2-tailed) .000 
N 100 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
 
There was significant correlation between BMI and neck 
circumference  with the p value significant (p< 0.001). 
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BMI VS WAIST HIP RATIO 
W/H Pearson Correlation .213
*
 
Sig. (2-tailed) .034 
N 100 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
 
This table shows the linear correlation of BMI  and  waist hip ratio 
with a significant probability value of 0.034. 
Correlation of body mass index and waist hip ratio  
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NECK CIRCUMFERENCE VS WAIST HIP RATIO 
NECK C Pearson Correlation .178 
Sig. (2-tailed) .077 
N 100 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
 
The correlation of neck circumference and waist hip ratio was not 
statistically significant. 
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DURATION VS FUNDUS GRADE 
GRADE Pearson 
Correlation 
.507
**
 
Sig. (2-tailed) .000 
N 100 
 
*. Correlation is significant at the 0.05 level (2-tailed). 
**. Correlation is significant at the 0.01 level (2-tailed). 
 
This study showed a positive correlation of duration of diabetes 
with retinopathy grade with the significant p value <0.001. 
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BMI VS FUNDUS GRADE IN FEMALES 
 
BMI_interval 
Total 1.00 2.00 3.00 4.00 
GRADE 0 1 14 13 3 31 
1 0 1 7 6 14 
2 0 1 2 1 4 
3 0 1 0 0 1 
Total 1 17 22 10 50 
a. SEX = F 
 
Chi-Square test 
 
Value df 
Asymp. Sig. (2-
sided) 
Pearson Chi-Square 12.271
a
 9 .198 
Likelihood Ratio 13.615 9 .137 
Linear-by-Linear 
Association 
.009 1 .925 
N of Valid Cases 50   
 
a. 12 cells (75.0%) have expected count less than 5. The minimum 
expected count is .02. 
b. SEX = F 
In females, the body mass index does not have significant 
statistical correlation with the grading of diabetic retinopathy. 
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GRADE * BMI_interval 
 
 
BMI_interval 
Total 2.00 3.00 4.00 
GRADE 0 12 14 1 27 
1 5 9 4 18 
2 0 1 3 4 
3 0 0 1 1 
Total 17 24 9 50 
a. SEX = M 
Chi-Square Tests
b
 
 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 17.990
a
 6 .006 
Likelihood Ratio 16.515 6 .011 
Linear-by-Linear 
Association 
12.097 1 .001 
N of Valid Cases 50   
a. 8 cells (66.7%) have expected count less than 5. The minimum 
expected count is .18. 
b. SEX = M 
 
In males, our  study showed the positive correlation of BMI grade 
and fundus grade in males with p value of 0.006. 
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DURATION OF DIABETES VS BMI AND  GRADE 
DURATION Pearson Correlation .354
**
 .507
**
 
Sig. (2-tailed) .000 .000 
N 100 100 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
 
Duration of diabetes had a positive correlation with grading of 
retinopathy and BMI.  
URINE SPOT PCR VS BMI 
URINE PCR Pearson Correlation .208
*
 
Sig. (2-tailed) .038 
N 100 
 
Urine spot PCR had a positive correlation with  body mass index 
with p value 0.038 
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TGL VS FUNDUS GRADE 
TGL Correlation Coefficient .241
*
 
Sig. (2-tailed) .016 
N 100 
 
TGL had a direct positive correlation with diabetic retinopathy 
grade with p value of 0.016. 
CHOLESTEROL VS NECK CIRCUMFERENCE AND BMI 
CHOLESTEROL Pearson Correlation .302
**
 .305
**
 
Sig. (2-tailed) .002 .002 
N 100 100 
**. Correlation is significant at the 0.01 level (2-tailed). 
 
Cholesterol  has a positive correlation with  neck circumference 
and  BMI 
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SYSTOLIC AND DIASTOLIC BLOOD PRESSURE VS GRADE 
SBP Pearson Correlation -.117 
Sig. (2-tailed) .247 
N 100 
DBP Pearson Correlation -.027 
Sig. (2-tailed) .793 
N 100 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
 
In our study there was a negative correlation of systolic and 
diastolic blood pressure with degree of fundal retinopathy. 
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MILD NON PROLIFERATIVE DIABETIC 
RETINOPATHY WITH CSME 
 
 
 
MODERATE NON PROLIFERATIVE DIABETIC 
RETINOPATHY 
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PROLIFERATIVE DIABETIC RETINOPATHY 
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DISCUSSION 
Our study had equal number of male and female patients to avoid 
confounding factors. Type 2 diabetes patients were  more in this study 
compared to type 1 diabetes which indirectly implies that prevalence of 
type 2 diabetes was more. 
For more than thirty years it was thought  poor glycemic control, 
poor blood pressure and longer duration of diabetes were only  found to 
affect the occurrence and progression of diabetic retinopathy but later 
newer studies like ADVANCE 
[96]
 Action in Diabetes and Vascular 
Disease and the Action to Control Cardiovascular Risk in Diabetes 
ACCORD
[97]
-Eye proved that other factors too play a role in progression 
of diabetic retinopathy. Other modifiable risk factors has to be thoroughly 
studied. 
Hence in our study, we  aimed at  studying  the correlation of 
anthropometric changes   and severity of diabetic retinopathy in  the study  
population of hundred diabetics. This clinical study showed the positive 
association of body mass index and neck circumference with the severity 
of diabetic retinopathy in males.  
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BMI AND RETINOPATHY  
Many studies have been conducted  globally, to prove the 
correlation  of anthropometric parameters  such as body mass index  with 
diabetic retinopathy.   Diabetic Control and Complication Trial
[98]
 showed 
that body mass index had  positive association with the diabetic 
retinopathy. Another study  by hoorm
[99]
  analysed 2484 patients and 
concluded that there was linear correlation of diabetic retinopathy with 
BMI, but the draw back with that study again was they had not included 
other anthropometric measurements like waist, hip circumference and 
waist hip ratio. 
Singapore study (SiMES) 
[100]
( 2004- 2006) –a  multivariate 
analysis  reported  that there existed a negative correlation between body 
mass index and diabetic retinopathy. The drawback regarding that study 
was that, it didn’t include the educational status, duration of diabetes and 
economic status of the patients, limited sample size of  only eighty 
members and only random blood sugar was used to diagnose diabetes 
which was obviously not the proper diagnostic test. Sankara Nethralaya 
Diabetic Retinopathy Epidemiology And Molecular genetic Study (SN-
DREAMS-I) conducted a study in urban  parts of India which comprised 
30% of Indian population. With the cut off value for  obesity  as BMI ≥ 
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23kg/m
2
 and WC ≥ 90cm in males and ≥ 80cm in females, there was a  
positive relationship   between  abdominal obesity and increased waist 
hip ratio with  diabetic retinopathy among females. Limitation of this 
study  was that only BMI was taken as the index for measuring obesity 
but other  anthropometric parameters were not included. 
Wisconsin Epidemiologic Study of  Diabetic Retinopathy
[101]
 group 
conducted the study with thousand three hundred and seventy patients 
aged thirty or older and concluded  that lower body mass index correlated 
with the severity of diabetic retinopathy and later after twenty years the 
WESDR group showed the positive correlation of body mass index with  
retinopathy in insulin dependent diabetes. Raman et al and Looker et al 
mentioned that lower body mass was associated with diabetic retinopathy, 
contributing that diabetic patients have a mind set of reducing weight 
once  the diagnosis of diabetes is established. In 1986, Ballard et al and 
Boyvada et al  in 2003 and Van Leiden et al in 2005  showed that 
increased body mass index was associated with severe diabetic 
retinopathy. 
 
 93 
GENDER DIFFERENCES IN RETINOPATHY 
  According to study conducted by Janghorbani et al [30], gender 
had no role in the severity of diabetic retinopathy.  Brandon et al showed 
that Indian women had more abdominal fat. WESDR 
[101]
emphasized that 
males were more prone for  severe diabetic retinopathy. In our study, 
female had less severity, the reason has to be evaluated with  large 
number of population and  by taking equal number of participants in 
underweight, normal weight, overweight, obese in both males and 
females. 
        We were able to find that most of the diabetics in our study  had 
mild retinopathy both in normal weight and in over weight. World Health 
Organisation declared the healthy  body mass  for Asians is 18.5 -22 kg 
/m
2
. Compared to other ethnic groups, Indians have less BMI. If the BMI 
interval according to Asian Indian cut off were used, more number of 
patients would have fallen into obese category  and linearly the 
proportion of patients with moderate and severe retinopathy would 
increase. In  our clinical study, amongst females,  neck circumference, 
waist hip ratio  and  duration  of diabetes were strongly associated with 
each other and with the retinopathy changes in diabetics  but BMI did not  
have a statistically significant correlation. The reason behind this might 
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be that equal number of participants were not recruited in each arm of 
BMI interval  in females. Whereas in males BMI, neck circumference and 
duration of diabetes were associated with each other but waist hip ratio 
was not found to be associated. Urine spot PCR had a positive 
correlation with  body mass index and negative correlation with systolic 
blood pressure, diastolic blood pressure, neck circumference  in this 
clinical study. Systolic and diastolic blood pressure did not correlate with 
diabetic retinopathy grade in our study. Badaruddoza et al studied  
relationship of  waist hip ratio, BMI and blood pressure among the  
Punjabi Sikh and Hindu females and concluded that they had positive 
correlation with each other. 
Advantages of measuring neck circumference: 
There exists a linear correlation of waist-hip circumference, waist 
hip ratio, neck circumference, serum lipids with diabetic retinopathy. 
Hence, neck circumference could be used independently   to measure 
central obesity or upper body fat.  Also, neck circumference and serum 
lipid levels namely serum cholesterol and triglyceride  were positively 
correlated, which indicates that  neck circumference could be used a 
useful indicator for metabolic syndrome and instead of measuring weight 
and height and computing the formula of body mass index, neck 
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circumference can be easily measured. Cultural dilemma exists while 
measuring the waist circumference and hip circumference among the 
females, where neck circumference measurements would be easily 
acceptable and neck circumference can well be proclaimed as a surrogate 
marker of cardio metabolic disease. Duration of diabetes had positive 
correlation with diabetic retinopathy grade. J.L. Gross1 et al in 2006 
concluded that the duration of diabetes had a positive correlation of 
diabetic retinopathy grade. 
WAIST CIRCUMFERENCE VS  WAIST HIP RATIO . 
Sunita et al study  reported that waist  circumference was a better 
surrogate marker of body mass index than waist hip ratio.  In the above  
study, they proclaimed that  waist hip ratio measures the regional 
distribution of fat rather than  the measurement of central obesity through 
waist circumference. According to our study, the waist hip ratio and the 
waist circumference goes hand in hand with body mass index and with 
the   severity of diabetic retinopathy. Asian cut off value for normal waist 
circumference were 85 and 80 cm for men and women and waist hip ratio   
were 0.89 and  0.81   for men and women respectively.  
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In 2001, first cross sectional study was conducted by Ben – noun et 
al. 3  to find out any association between neck circumference and  
obesity, and to identify if obesity can be recognised only by measuring 
the neck circumference. He showed  in the results   that, neck 
circumference of greater than 37 cm and 34 cm in male and female 
respectively, was associated with overweight/obesity. The prevalence of  
diabetic retinopathy had a linear association till the BMI of 26-29.9% and 
for diabetic nephropathy linear correlation exist for BMI of > 30 . The 
Chennai Urban Rural Epidemiology Study (CURES) Eye Study—2 by M  
Rema et al in 2006 showed that  there was  a positive  correlation 
between triglycerides and diabetic retinopathy and macular edema. Our 
study concluded that  serum cholesterol and triglycerides had a positive 
correlation with diabetic retinopathy. 
LIMITATION; 
 The results might not be generalised to other ethnic groups due to 
varied cultural practices, eating habits and physical work and 
varying urbanisation as the study was performed in urban 
population. 
 In this study the body mass index was classified according to the 
western standards. 
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 Neck circumference was concluded as a surrogate marker of 
obesity but there was no radiographic quantification measures to 
prove this fat distribution. 
 This study included  only hundred diabetic patients. Further studies 
with large number of sample size has to be undertaken in order to 
reiterate this fact. 
FUTURE IMPLICATION: 
 Healthy food habits, and increased physical activity has to be 
encouraged for it is the most important intervention in reducing the 
risk of future development of lifestyle disorders. 
 Diabetic patients have to be screened periodically as per 
international/ national guidelines, to avoid the consequences of 
retinopathy and vision loss. 
 Neck circumference is considered to be a surrogate marker of 
central obesity . 
 Use of Angiogenesis inhibitors  has to be evaluated in obesity.  
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CONCLUSION 
From the study ,as the  body mass index ,neck circumference   
increases, the severity of retinopathy increases in males , where  as waist 
hip ratio does not have positive correlation with grade of retinopathy 
.Neck circumference has significant correlation with grade of  diabetic 
retinopathy.   
 
In females,  the body mass index does not  have  statistically  
significant  correlation with diabetic retinopathy .Neck circumference, 
waist cizc rcumference, waist hip ratio have positive correlation with DR. 
 Duration of diabetes has positive correlation with diabetic retinopathy 
and BMI. Urine spot PCR had a positive correlation with body mass 
index. 
Hence in diabetics anthropometric measures help in predicting the 
micro vascular complications such as retinopathy and nephropathy. 
Therefore such simple noninvasive  anthropometric  measures have to be 
undertaken routinely while following up the patients.  
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ABBREVIATIONS 
 
DM   - DIABETES MELLITUS 
DR   - DIABETIC RETINOPATHY 
IHD    – ISHAEMIC HEART DISEASE 
WHO   - WORLD HEALTH ORGANISATION 
BMI   - BODY MASS INDEX 
SBP   -  SYSTOLIC BLOOD PRESSURE 
DBP   - DIASTOLIC BLOOD PRESSURE 
WT   - WEIGHT 
HT   - HEIGHT 
W/H   - WAIST TO HIP RATIO 
FBS   - FASTING BLOOD SUGAR 
PPBS   - POST PRANDIAL BLOOD SUGAR 
HBA1C  - GLYCATED HEMOGLOBIN 
TGL   - TRIGLYCERIDES 
HDL   - HIGH DENSITY LIPOPROTEIN 
LDL   - LOW DENSITY LIPOPROTEIN 
VLDL  - VERY LOW DENSITY LIPOPROTEIN 
AGE   - ADVANCED GLYCATED END PRODUCTS 
VEGFR  - VASCULAR ENDOTHELIAL GROWTH  
    FACTOR 
IL-6   - INTER LEUKIN 6 
PAI   - PLASMINOGEN ACTIVATOR INHIBITOR 
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FFA   - FREE FATTY ACID 
FGF   - FIBROBLAST GROWTH FACTOR 
MMP   - MATRIX METALLOPROTEINASE. 
PKC   - PROTEIN KINASE C 
ECM   - EXTRA CELLULAR MATRIX 
IOTF   - INTERNATIONAL OBESITY TASK FORCE 
DCCT  - DIABETIC CONTROL AND  
    COMPLICATION TRIAL 
UKPDS  - UK PROSPECTIVE DIABETIC STUDY 
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DATA COLLECTION FORM 
 NAME 
 AGE 
 SEX: 
 OCCUPATION: 
 ADDRESS: 
  OP NO  
  DURATION OF DIABETES, YR 
 MEDICATIONS 
  OCULAR SYMPTOMS 
 CURRENT/PAST SMOKER, PACK/YEAR 
 SYSTOLIC BLOOD PRESSURE, MM HG  
  DIASTOLIC BLOOD PRESSURE, MM HG  
  ECG 
  WEIGHT, KG 
  HEIGHT, M 
  BODY MASS INDEX, KG/M2 
  WAIST CIRCUMFERENCE, CM 
 WAIST TO HIP RATIO, CM  
  NECK CIRCUMFERENCE, CM  
 FASTING PLASMA GLUCOSE, MG/DL 
 POST PRANDIAL SUGAR MG/DL 
  TOTAL CHOLESTEROL, MG/DL 
  TRIGLYCERIDES, MG/DL 
 RETINOPATHY GRADE 
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NO NAME AGE SEX TYPE YRS SBP DBP WT HT BMI WAIST HIP W/H N C FBS PPBS 
URINE 
PCR CHOLESTEROL TGL FUNDUS GRADE 
1 MAHESWARI 48 F II 7 130 76 78 156.5 31.84 97 108 0.89 37.5 220 280 0.38 230 216 MILD NPDR 1 
2 VASANTHAN 62 M II 8 140 78 88 164 32.71 90 102 0.88 35.5 246 300 0.28 278 158 MILD NPDR 1 
3 SARASWATHI 54 F II 5 149 98 67 160 26.17 82 95 0.86 34 186 226 0.01 208 156 NIL 0 
4 SHANTHI 34 F I 8 129 78 62 162 23.6 76 90 0.84 31 183 228 0.29 216 164 NIL 0 
5 MURUGESAN 42 M II 5 128 72 78 168 27.63 86 92 0.93 34 218 268 0.32 222 167 NIL 0 
6 KUTTIAMAL 52 F II 8 116 70 64 156 25.4 84 102 0.82 33.5 178 190 0.34 176 142 NIL 0 
7 SUBRATHA 42 F II 4 134 82 60 149 27.02 81 96 0.84 31 162 188 0.18 186 161 NIL 0 
8 KALA 52 F II 7 146 84 68 152 29.43 98 106 0.92 36 190 285 0.42 207 232 MILD NPDR WITH CSME 1 
9 VALLI 38 F I 10 138 86 66 162 28.95 89 98 0.9 34.5 219 239 0.32 243 156 MILD NPDR 1 
10 SELVAM 46 M II 6 126 84 66 156.5 26.94 86 96 0.89 33 218 256 0.07 221 172 NIL 0 
11 MUTHUMEENA 63 F II 12 136 78 83 157.5 33.45 110 118 0.93 35.5 224 288 0.33 234 179 MOD NPDR 2 
12 BANUMATHI 40 F II 6 128 76 70 154.5 29.32 89 110 0.8 35 154 312 0.54 264 168 NIL 0 
13 NADHA 56 M II 7 134 84 67 156.5 27.35 97 102 0.95 35.5 187 195 0.21 258 150 MILD NPDR 1 
14 SAKUNTHALA 48 F II 5 126 70 59 158 23.63 84 102.5 0.81 33.5 232 254 0.26 225 192 NIL 0 
15 ALI 45 M II 8 132 84 78 166 28.3 98 107 0.91 37 214 326 0.28 211 134 MILD NPDR 1 
16 SARAVANAN 56 M II 7 144 88 60 158 24.03 96 106 0.9 38 342 365 0.47 378 198 MILD NPDR 1 
17 VIJAYAN 36 M I 8 132 76 58 159 22.94 87.9 93 0.94 33.4 217 253 0.29 214 172 nil 0 
18 GOWRI 45 F II 5 138 84 56 146 26.27 78 98 0.79 32 256 298 0.21 256 113 nil 0 
19 NOORNISHA 49 F II 6 152 84 78 156 32.05 89 104 0.85 34 238 267 0.31 258 146 MILD NPDR 1 
20 LAKSHMI 54 F II 6 132 88 66 160 25.78 92 116 0.79 33 254 267 0.12 276 150 NIL 0 
21 MAIKAMMAL 62 F II 8 126 84 67 154 28.25 94 102 0.92 32 264 306 0.39 312 143 MILD NPDR 1 
22 HEMAVATHI 59 F II 9 132 68 62 156.5 25.31 96 102 0.94 34 247 284 0.31 267 152 NIL 0 
23 MANIKKAM 51 M II 7 138 82 72 158 28.84 88 106 0.83 36 183 290 0.37 269 156 NIL 0 
24 JAYAKANDHAM 35 F I 5 142 84 56 158 22.43 93 116 0.8 32 182 278 0.11 284 149 NIL 0 
25 SARUMATHY 64 F II 9 139 76 54 162 20.57 85 98 0.86 32 173 265 0.42 178 135 NIL 0 
26 SUGIRITHA 49 F II 4 146 88 64 162 24.38 78 89 0.87 37 263 252 0.18 167 152 NIL 0 
27 SHIVA 53 M II 8 148 90 80 153 34.17 89 106 0.83 36 257 306 0.04 285 187 MILD NPDR 1 
28 DHALAYAN 59 M II 6 134 82 74 161.5 28.37 92 118 0.77 35 276 261 0.3 276 205 NIL 0 
29 VANI 48 F II 9 128 78 68 166 24.67 98 108 0.9 36.5 303 349 0.21 243 184 MOD NPDR 2 
30 GAUTHAMAN 52 M II 12 156 72 72 149 32.43 109 118 0.923 39 296 379 0.38 278 254 SEVERE PDR 3 
31 KUPPAN 56 M II 8 150 82 78 162 29.72 92 104 0.88 36 218 265 0.16 244 156 NIL 0 
32 SEKAR 47 M II 5 146 76 66 160 25.7 88 99 0.88 33 176 245 0.34 215 188 NIL 0 
33 AHJA MOIHEED 58 M II 9 160 82 56 158 22.43 84 103 0.81 35 153 178 0.21 220 156 NIL 0 
34 IYAPPAN 30 M I 10 126 74 72 158 28.84 94 114 0.82 36 198 267 0.24 284 139 MILD NPDR 1 
35 VASU 59 M II 6 138 82 58 170 20 86 95 0.9 34.5 278 315 0.54 236 132 NIL 0 
36 USMAN 63 M II 9 142 88 70 164 26.02 90 98 0.91 36 317 386 0.37 167 183 MILD NPDR 1 
37 VADIVEL 28 M I 8 118 68 62 158 24.8 79 88 0.89 30 249 256 0.11 234 115 MILD NPDR 1 
38 GUNALAN 54 M II 9 140 72 69 159 27.2 102 118 0.86 35 252 267 0.27 167 122 NIL 0 
39 VINCET 26 M I 6 126 72 58 157 23.53 95 106 0.89 32 152 179 0.17 189 149 MILD NPDR 1 
40 BALU 54 M II 8 156 84 73 161 28.16 99 111 0.89 33 178 190 0.55 278 196 NIL 0 
41 GANESAN 48 M II 7 142 88 59 155 24.55 83 96 0.86 31 277 343 0.63 163 143 NIL 0 
42 MURUGAVEL 45 M II 5 136 72 66 162 25.14 79 89 0.88 32 318 356 0.44 182 256 MILD NPDR 1 
43 ELUMALAI 62 M II 4 124 70 61 159 24.12 85 94 0.9 34 246 289 0.51 299 357 NIL 0 
44 BALAJI 43 M II 6 132 82 64 156 26.29 93 106 0.87 35 215 267 0.32 321 253 NIL 0 
45 MANIVEL 59 M II 10 148 80 72 158 28.8 80 109 0.73 34.5 283 346 0.18 216 217 NIL 0 
46 VANI 46 F II 11 156 76 88 160 34.37 82 95 0.86 34 166 189 0.13 256 137 MILD NPDR 1 
47 GOWRI 61 F II 5 162 92 76 162 28.95 93 106 0.87 33 153 168 0.01 214 158 NIL 0 
48 KUMAR 54 M II 8 154 86 82 157 33.26 84 98 0.85 35 178 215 0.23 175 177 NIL 0 
49 KALYANI 47 F II 6 148 74 76 158 30.44 82 94 0.87 34 122 162 0.43 269 209 MILD NPDR 1 
50 KASTHURI 49 F II 9 132 82 72 155 29.96 94 102 0.92 37 287 365 0.29 283 156 MILD NPDR 1 
 
 122 
NO NAME AGE SEX TYPE YRS SBP DBP WT HT BMI WAIST HIP W/H N C FBS PPBS 
URINE 
PCR CHOLESTEROL TGL FUNDUS GRADE 
51 NAVEEN THARABAI 60 F 2 5 130 80 60 143 29.3 102 114.5 0.89 36.5 181 240 0.4 230 298 MODERATE NPDR 2 
52 RAJESHWARI 54 F 2 6 142 84 60 154 25.2 110 118 0.93 35.5 109 226 0.21 278 138 MILD NPDR 1 
53 LAKSHMI 66 F 2 5 148 88 65 146 30.4 105 107 0.98 33 128 233 0.28 189 162 NO EVIDENCE 0 
54 LALITHA 68 F 2 8 150 90 50 142.5 24.62 73 98 0.744 32 138 186 0.18 184 152 NO EVIDENCE 0 
55 PONNAMMAL 55 F 2 7 144 92 53 150 23.55 76 95 0.8 33 136 244 0.01 218 178 NO EVIDENCE 0 
56 MYMUBEE 54 F 2 6 138 88 86 164 31.9 98 112 0.87 35 116 216 0.26 278 178 MILD NPDR 1 
57 SELVAM 45 M 2 8 148 94 72 164 26.76 96 108 0.88 36 184 214 0.41 220 148 NO EVIDENCE 0 
58 AMEENA 55 F 2 4 118 78 48 152 20.77 78 92 0.84 32.5 219 254 0.28 190 130 NO EVIDENCE 0 
59 ELANGO 49 M 2 9 136 88 72 165.5 26.28 86 92 0.93 37 136 199 0.17 188 152 MILD NPDR 1 
60 DHANASEKAR 56 M 2 12 158 102 92 166 33.38 103 115 0.89 35 88 188 0.29 254 116 MILD NPDR 1 
61 ALAMELU 56 F 2 15 126 82 60 158 24.03 93 103 0.9 33 194 248 0.36 191 142 MILD NPDR 1 
62 AFRAS 58 M 2 5 144 92 62 164 23.05 98 103 0.95 34.5 198 214 0.16 232 186 NO EVIDENCE 0 
63 SULOCHANA 40 F 2 7 136 80 56 159 22.15 84 90 0.93 32 116 168 0.28 308 178 NO EVIDENCE 0 
64 SAROJA 45 F 2 5 154 92 58 146.5 27.02 94 102 0.92 33 188 246 0.33 189 148 NO EVIDENCE 0 
65 RAJA 62 M 2 6 138 86 70 158.5 27.86 107 118 0.9 38 198 216 0.19 228 179 MILD NPDR 1 
66 MARIAMMAL 38 F 2 4 126 82 48 154 20.23 72 88 0.81 28 156 233 0.44 176 134 NO EVIDENCE 0 
67 AMARAVATHI 68 F 2 6 144 86 60 150 26.66 102 119 0.85 38 216 284 0.18 258 184 MILD NPDR 1 
68 KARUPPAYI 45 F 2 7 142 82 78 162.5 29.53 95 101 0.94 37 85 147 0.35 188 142 NO EVIDENCE 0 
69 MANNIKKAM 60 M 2 10 160 100 88 172 29.74 96 104 0.92 35.5 186 248 0.28 287 153 MILD NPDR 1 
70 SHERIFF 52 M 2 12 130 88 106 164 39.41 98 118 0.83 38 225 297 0.45 264 202 MODERATE NPDR 2 
71 CHANDRAN 49 M 2 8 126 84 62 160 24.21 82 102 0.8 33 210 266 0.28 247 127 NO EVIDENCE 0 
72 BASHA 58 M 2 15 138 92 82 172 27.71 86 108 0.79 36 232 398 0.62 302 256 MODERATE NPDR,CSME 2 
73 SUBATHRA 56 F 2 9 140 86 78 158 31.24 103 116 0.88 38 128 212 0.48 234 158 NO EVIDENCE 0 
74 SELVAMANI 48 M 2 7 148 92 68 164 25.28 88 102 0.86 33 188 246 0.35 278 178 NO EVIDENCE 0 
75 PREMA 64 F 2 3 146 94 51 158 20.42 84 103 0.81 34.5 214 324 0.29 188 124 NO EVIDENCE 0 
76 CHANDRAVADHANAM 62 M 2 8 138 88 82 156 33.69 96 114 0.83 36 320 356 0.52 294 182 MILD NPDR 1 
77 PRIYA 19 F 1 3 118 80 35 143 17.11 71 82 0.86 27 92 108 0.18 174 132 NO EVIDENCE 0 
78 MANIVANNAN 42 M 2 4 144 98 62 169 21.7 84 116 0.72 37.5 198 226 0.31 172 148 NO EVIDENCE 0 
79 MAMUDA 50 F 2 7 134 82 56 149 25.22 88 102 0.86 34 247 289 0.28 198 162 NO EVIDENCE 0 
80 VIJAYAN 49 M 2 12 140 80 68 160 26.5 99 108 0.91 38 226 299 0.38 244 143 MILD NPDR 1 
81 RAJENDRAN 52 M 2 7 140 80 54 164 20.07 76 94 0.8 34 203 288 0.24 194 137 NO EVIDENCE 0 
82 VASUMATHI 29 F 1 7 128 72 64 162 24.38 82 96 0.85 34 161 193 0.32 169 142 MILD NPDR 1 
83 JAYALAKSHMI 44 F 2 7 138 82 62 158 24.83 90 108 0.83 34 192 276 0.17 186 134 NO EVIDENCE 0 
84 SATHYABAMA 51 F 2 12 154 94 54 150 24 87 92 0.94 32 143 175 0.19 222 158 NO EVIDENCE 0 
85 KOTAGIRI 52 M 2 10 148 88 98 174 32.36 114 122 0.93 41 185 202 0.48 282 214 MODERATE NPDR 2 
86 VENKATESAN 58 M 2 8 142 88 68 161 26.23 86 98 0.87 46 243 287 0.22 248 179 NO EVIDENCE 0 
87 SANKARAN 52 M 2 7 128 76 62 168 21.96 86 102 0.8 35 146 285 0.32 232 155 NO EVIDENCE 0 
88 ANANDA NAIDU 56 M 2 5 148 90 56 164 20.82 83 104 0.79 36 116 211 0.24 254 139 NO EVIDENCE 0 
89 MAHABUBEE 60 F 2 8 136 82 56 149 25.22 89 96 0.92 30 89 123 0.12 241 162 NO EVIDENCE 0 
90 SABEERA BEGAUM 56 F 2 4 136 74 62 152 26.83 76 95 0.8 32 144 168 0.21 214 158 NO EVIDENCE 0 
91 RENGANATHAN 54 M 2 10 134 72 62 160 24.21 96 100 0.96 35 162 198 0.28 244 159 MILD NPDR 1 
92 THIRUPURAM 54 F 2 12 116 74 45 146 21.11 70 99 0.7 32 211 257 0.19 245 139 NO EVIDENCE 0 
93 KUPPAMMAL 62 F 2 6 138 84 79 164 29.37 104 108 0.96 37 252 289 0.64 218 143 MILD NPDR 1 
94 MOHAMMED 39 M 2 10 154 92 72 160 28.12 98 106 0.92 34 218 253 0.32 154 168 NO EVIDENCE 0 
95 PRABAVATHI 50 F 2 12 126 76 88 160 34.375 90 103 0.87 31 222 286 0.54 198 138 NO EVIDENCE 0 
96 VARADHAN 55 M 2 11 128 80 92 168 32.59 102 112 0.91 38 208 316 0.41 292 188 MODERATE NPDR 2 
97 ZAHITHA 52 F 2 7 142 94 88 148 40.17 110 124 0.88 42 278 332 0.37 266 182 MILD NPDR 1 
98 ELLAMMAL 54 F 2 12 120 88 65 154 27.4 99 104 0.95 36 216 248 0.32 259 169 MODERATE NPDR 2 
99 JEYARAMAN 60 M 2 7 142 80 70 168 24.8 94 102 0.92 34 264 392 0.16 262 164 MILD NPDR 1 
100 BALU 54 M 2 8 138 78 62 166 22.49 76 88 0.86 33 214 258 0.06 217 189 NIL 0 
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